Novel antibodies for leading cause of neonatal sepsis
Arsanis focuses on the discovery and development of novel monoclonal antibodies (mAbs) to prevent and treat infectious disease. The foundation is working with Arsanis to develop a prophylactic mAb candidate targeting Stap aureus, a leading cause of neonatal sepsis that leads to around 345,000 annual deaths globally.
-
Domain
-
Investment typeDirect equity
-
StatusExit
-
Initial investmentSeries D
-
Partnered in2017
-
HeadquartersUSA
-
Program strategyDiscovery & Translational Sciences
More about our work
Our focus
Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.
Investment approach
Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.
Our team
We bring depth of experience to every investment, with a proven track record across sectors and scale.